Surien Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 2.16 Cr
- Company Age 20 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 20.21 Cr
- Satisfied Charges ₹ 6.06 Cr
- Revenue Growth -22.71%
- Profit Growth 18.60%
- Ebitda -2.24%
- Net Worth 1.23%
- Total Assets -21.41%
About Surien Pharmaceuticals
Surien Pharmaceuticals Private Limited (SPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 19 April 2004 and has a history of 20 years and nine months. Its registered office is in Chennai, Tamil Nadu.
The Corporate was formerly known as Shince Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.16 Cr.
The company currently has active open charges totaling ₹20.21 Cr. The company has closed loans amounting to ₹6.06 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ramasamy Krishnamoorthy, Gowri Krishnamoorthy, and Chathurappan Anbazhagan serve as directors at the Company.
Company Details
-
LocationChennai, Tamil Nadu
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24232TN2004PTC053031
-
Company No.
053031
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
19 Apr 2004
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Surien Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramasamy Krishnamoorthy
|
Managing Director | 21-Apr-2007 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Gowri Krishnamoorthy
|
Director | 21-Apr-2004 | Current |
|
Chathurappan Anbazhagan
|
Whole-Time Director | 11-Oct-2018 | Current |
Financial Performance of Surien Pharmaceuticals.
Surien Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 22.71% decrease. The company also saw a substantial improvement in profitability, with a 18.6% increase in profit. The company's net worth moved up by a moderate rise of 1.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Surien Pharmaceuticals?
In 2023, Surien Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sonivar Pharma Private LimitedRamasamy Krishnamoorthy and Gowri Krishnamoorthy are mutual person
-
Shince Pharmaceuticals Private Limited
Ramasamy Krishnamoorthy and Gowri Krishnamoorthy are mutual person
-
Chennai Jk Studio Technologies Private Limited
Ramasamy Krishnamoorthy and Gowri Krishnamoorthy are mutual person
Charges (Loans)
₹20.21 Cr
₹6.06 Cr
Charges Breakdown by Lending Institutions
- Others : 11.29 Cr
- State Bank Of India : 8.92 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Dec 2023 | Others | ₹5.20 M | Open |
| 22 Sep 2022 | Others | ₹10.77 Cr | Open |
| 04 Sep 2010 | State Bank Of India | ₹8.92 Cr | Open |
| 31 Oct 2016 | Others | ₹1.00 Cr | Satisfied |
| 10 Jan 2009 | Karnataka Bank Limited | ₹1.00 Cr | Satisfied |
How Many Employees Work at Surien Pharmaceuticals?
Unlock and access historical data on people associated with Surien Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Surien Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Surien Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.